Clinical Trial

Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)

Study acronym: PANDA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of cardiovascular diseases will result in a reduced incidence of SIRS and MODS.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-23; most recent amendment 2024-11-20.
Status change: Not Yet Recruiting → Recruiting 2024-11-17
Trial Details
NCT Number NCT06195267
Lead Sponsor Nanjing Medical University
Collaborators: The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital
Conditions Aortic Dissection, Systemic Inflammatory Response Syndrome, Cardiovascular Diseases (CVD)
Enrollment 500 participants
Start Date 2024-07-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-22